The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas

Diabetologia

Volumn 40, Issue 7, 1997, Pages 764-769

  Murata, T ^a   Nagai, R ^b   Ishibashi, T ^a   Inomata, H ^a   Ikeda, K ^b   Horiuchi, S ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Advanced glycation end products; Blood retinal barrier; Diabetic retinopathy; N( ) (carboxymethyl)lysine; Vascular endothelial growth factor

Indexed keywords

EPITOPE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL WALL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GLYCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUELLER CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RETINA; RETINA NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; ANTIBODIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENDOTHELIAL GROWTH FACTORS; EPITOPES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; LYSINE; MALE; MIDDLE AGED; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030805762     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050747     Document Type: Article

References (40)

1. Davis MD (1990) Diabetes mellitus. In: Gold DH, Weingeist TA (eds) The eye in systemic disease. Vol 1. J. B. Lippincott Company, Philadelphia, pp 79-85
2. Tolentino MJ, Miller JW, Gragoudas ES, et al. (1996) Intravitreous injection of vascular endothelial growth factor produce retinal ischaemia and microangiopathy in adult primate. Ophthalmology 103: 1820-1828
3. Klein R, Klein BEK, Moss SE, Cruickshanks KJ (1995) The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV. The long-term incidence of macular oedema. Ophthalmology 102: 7-16
4. Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H (1995) Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 27: 48-52
5. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K (1996) The relation between expression of vascular endothelial growth factor and breakdown of blood-retinal barrier in diabetic rat retinas. Lab Invest 74: 819-825
6. Aiello LP, Avery RL, Arrigg PG et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487
7. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 72: 638-645
8. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039
9. Ferrara N, Houck K, Jakeman L, Leung DW (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13: 18-32
10. Minchenko A, Bauer T, Salceda S, Caro J (1994) Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 71: 374-379
11. Senger DR, Van de Water L, Brown LF et al. (1993) Vascular permeability factor (VPF, VEGF), in tumor biology. Cancer Metastasis Rev 12: 303-324
12. Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845
13. Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM (1989) Aging of proteins: immunological detection of a glucose-derived pyrrole formed during Maillard reaction in vivo. J Biol Chem 263: 3758-3764
14. Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267: 5133-5138
15. Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321
16. Makino H, Shikata K, Hironaka K et al. (1995) Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 48: 517-526
17. Brownlee M (1994) Lilly lecture 1993. Glycation and diabetic complications. Diabetes 43: 836-841
18. Hammes HP, Weiss A, Hess S, Araki N, Horiuchi S, Brownlee M, Preissner T (1996) Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest 75: 325-338
19. Vlassara H, Bucala R, Striker L (1994) Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70: 138-151
20. Ahmed MU, Thorpe SR, Baynes JW (1986) Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261: 4889-4894
21. Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW (1991) Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30: 1205-1210
22. Sell DR, Monnier VM (1989) Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 264: 21597-21602
23. Nakamura K, Hasegawa T, Fukunaga Y, Ienaga K (1992) Crosslines A and B as candidates for the fluorophores in age- and diabetes-related cross-linked proteins, and their diacetates produced by Maillard reaction of a-N-acetyl-L-lysine with D glucose. J Chem Soc Commun 7: 992-994
24. ε-(Carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35: 8075-8083
25. ε-(Carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878
26. Horiuchi S, Araki N, Morino Y (1991) Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. J Biol Chem. 266: 7329-7322
27. Adamis AP, Kuroki M, Tolentino MJ, Kim I (1996) Advanced glycation end products (AGE) increase retinal VEGF gene expression. Invest Ophthalmol Vis Sci 37: 975 (Abstract)
28. Guesdon JL, Ternynck T, Avrameas S (1979) The use of avidin-biotin interaction in immunoenzyme techniques. J Histochem Cytochem 27: 1131-1139
29. Adamis AP, Shima DT, Tolentino MJ et al. (1996) Inhibition of vascular endothelial growth factor prevents retinal ischaemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114: 66-71
30. Aiello LP, Pierce EA, Foley ED et al. (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92: 10457-10461
31. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE (1996) Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 93: 4851-4856
32. Fischer S, Sharma HS, Karliczek GF, Schaper W (1995) Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine. Brain Res Mol Brain Res 28: 141-148
33. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD (1995) Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation 92: 11-14
34. Stavri GT, Hong Y, Zachary I et al. (1995) Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett 358: 311-315
35. Dominiczak MH (1991) The significance of the products of the Maillard (Browning) reaction in diabetes. Diabet Med 8: 505-516
36. Gardiner TA, Stitt AW, Anderson HR, Archer DB (1994) Selective loss of vascular smooth muscle cells in the retinal microcirculation of diabetic dogs. Br J Ophthalmol 78: 54-60
37. Yamagishi S, Yamamoto Y, Harada S, Hsu CC, Yamamoto H (1996) Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett 384: 103-106
38. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H (1989) Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 170: 1387-1407
39. Clauss M, Gerlach M, Gerlach H et al. (1990) Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172: 1535-1545
40. 2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 138: 213-221